New protocol for privacy in medical devices

30 01 2014

It is based on ISO standards and helps reduce costs


Etiqueta 'RDIF'.

Tag ‘ RDIF ’.

Iranian and Spanish researchers have designed a new authentication protocol that guarantees privacy and security in the communications that take place between medical devices implanted in patients by means of identification by radio frequency (RFID).

This new Protocol, based on the ISO standards, It has been developed by researchers at the universities Carlos III and Polytechnic and the University of Tehran, you ensure that the integration of systems 'eHealth' with RFID technology will contribute to reduce costs and to improve the monitoring and treatment of patients.


In particular, proposed RFID standards (ISO/IEC 9798 and 11770), as well as some public recommendations made by the National Institute of standards and technology (NIST) of United States, necessary to prevent that data stored on these devices are compromised computer attacks.

RFID systems are widely used today, many times without that are aware of it, as in the control of access to buildings, control fleets and goods, transport systems, the University cards or contactless payment systems.

However, This technology has not been very explored in medical environments, where there is a "broad and promising future" when it comes to medical follow-up patients from automatically, control taking of drugs so that there are no problems when it comes to your dosage or communicate with devices implanted in the human body, such as pacemakers, insulin pumps or cochlear implants.

This system is composed of a database, a reader and card. However, While communication between the reader and the database is considered safe, which occurs between a card and reader occurs through a susceptible of being spied by a third party communication channel, an attacker, that it could modify the information transmitted by this channel.

For this reason, the implementation of this technology has been in question in the absence of privacy and security of users.


Active cards, semiactivas or passive

For the RFID, Depending on the nature of the cards (also called tags), three groups could be established: enable, semiactivas or passive. The first possess an own power supply, causing them to transmit very high distances, they have no computer restrictions and are, In addition, the most expensive. Semiactivas cards are those that can obtain energy by means of an own source or by the reader; they transmit to shorter distance and are cheaper than the active.

Finally, the passive RFID are those cards that have no source of energy and need a reader to be able to transmit information; they are the cheapest, they transmit a few inches and possess strong computer restrictions.

The scientific community has focused on proposing new protocols that will ensure communication using tags passive as a challenge, since they do not support conventional cryptographic protocols (There are only a total of 1.200 logic gates intended to ensure communication between readers and tags).

However, in the vast majority of proposed protocols, the information belonging to users has been compromised. In general, This is due to two factors: the lack of rigorous standards in security protocols and analyses of security not formalized or little. [en línea] Madrid (ESP):, 30 de enero de 2014 [REF. 07 in January of 2014] Available on Internet: http://secciones/tecnologia/nuevo-protocolo-para-la-privacidad-en-dispositivos-medicos-2315

6 keys to the future of analytics

27 01 2014

A recently released report by Ewing Marion Kauffman Foundation proves the value of big data is certainly something to take seriously. And as more organizations create plans to make better use of and leverage their big data, Joe Petro, senior vice president of healthcare research and development at Nuance Communications, believes the industry is on the brink of seeing some pretty remarkable things as a result.

Petro outlines six keys to the future of analytics and big data in healthcare.

1. Organizations are “drowning in information, but dying of thirst” at the same time. According to Petro, one CMIO at Nuance sums up the current state of big data eloquently: “When you’re in the institution and you’re trying to figure out what’s going on and how to report on something, he says you’re dying of thirst in a sea of information,” he said. “And what he means by that is, there’s a tremendous amount of information but a big data problem, and the issue is how do we tap into that to make sense of what’s going on?” This question applies not only to the patient, Petro continued, but also to the government’s plans in regard to disease and population management. “The issue is it isn’t organized,” he said. “he saida mixture of structured and unstructured data, and what’s going to happen over the course of next several years is the government is imposing a tremendous amount of information for folks to report.”

2. Technologies that tap into big data will become more prevalent and ubiquitous. From a patient’s perspective, Petro said, analytics and big data will aid, for example, in determining which hospital in a patient’s immediate area is the best for treating their condition. “If I have a huge number of choices, today, you [determine that] by word of mouth,” he said. “But the government wants you to be able to look at a report card for various institutions, and the way to tap into the report card is to unlock all that information and impose regulations and reporting.” At the center of that, Petro continued, are the various types of IT used to tap into unstructured information, like dashboard technologies and analytics, business intelligence technologies, clinical intelligence technologies, and revenue cycle management intelligence for institutions. “These things will become more and more prevalent and ubiquitous … and [they] will become a lot more readily available to the patient.”

3. Decision support will be easier to access. In the institutions, Petro said, evidence-based medicine and decision support will become easier to access as a result of leveraging big data and analytics. “For example, if a patient is suffering from a particular condition, there’s a high potential something is going to happen to that patient because of their history,” he said. “That stuff is going to be brought up in the front of the care cycle, and the physician will be tapped on the shoulder, so to say.” Essentially, it’s about a lot more precise information at the point of care. “These are all the things that are going to tumble out of cracking the code, so to speak, of the big data problem.”

4. Information will flow more easily. Petro looked back to his days prior to working in health IT to remember what being in a hospital is like from a patient’s perspective. “I always remember sitting in a room with someone who’s sick, and you’re wondering what the heck is going on,” he said. “Then a physician comes in, and you’re afraid to talk to them.” He said there’s a lack of information flow, and a lack of ability for both physicians and patients to make choices. “The interesting part is, that happens all over the place within the workflow,” he said.he said“cracking the code” of big data, he continued, the flow of information not only will be easier for physicians, but will more easily extend to patients. “For example, I can tap on my cell phone and see there’s a 15-minute ED wait over here, and a five-minute wait over here. It’s making the availability of data more ubiquitous, and I think it’s going to come in plain and simple ways like that, and in more complicated ways, like diagnostic support and evidence-based medicine support in the workflow.”

5. Quality of care will increase to maintain revenues and drive costs down. From a cost perspective and a quality of care point of view, said Petro, there are a number of different areas that will be impacted. For example, if a patient experiences an injury while staying in a facility, the organization isn’t reimbursed for his/her care. “So the ability for a system to see that this [has the potential] to happen and alert everyone, so that type of thing doesn’t happen to me as a patient,” said Petsaid Petro;The one way the government is putting pressure on that is you won’t be compensated like the old days.” Through reporting, Petro predicts, these issues will become less and less common. “They’re going to tap into the information, and that’s just one example,” he said. “There are a whole bunch of things that could happen that are preventable and should be completely avoidable. After tapping into the information, I think that’s going to drive down the cost of healthcare.”

6. The physician-patient relationship will grow with the help of social media and mobile apps. And this all stems from the need for hospitals to keep patients healthy and out of their facilities, said Petro. “We have this whole notion of an ACO, and hospitals are going to start getting comped for keeping you healthy. In the old days, hospitals made money the sicker you are, and the longer they keep you there, the more they make.” Petro predicted that because of this, there will be an “explosion” of mobile applications and even social media, allowing patients to have easier access to nurses and physicians. “It’s about keeping [patients] healthy and driving down costs,” he said. “Those are the two major areas where there’s going to be a lot of stuff going on from a health information technology point of view, all underpinned by the availability of data, and tapping into that.”


Michelle McNickle, New Media Producer [en línea] Pensilvania (USA):, 27 in January of 2014 [REF. 08 in May of 2012] Available on Internet:

Antipsychotic drug exhibits cancer-fighting properties

23 01 2014

In zebrafish model, perphenazine activates therapeutic pathway for intractable leukemia, may hold promise for other tumors


In a prime example of finding new uses for older drugs, studies in zebrafish show that a 50-year-old antipsychotic medication called perphenazine can actively combat the cells of a difficult-to-treat form of acute lymphoblastic leukemia (ALL). The drug works by turning on a cancer-suppressing enzyme called PP2A and causing malignant tumor cells to self-destruct.

The findings suggest that developing medications that activate PP2A, while avoiding perphenazine’s psychotropic effects, could help clinicians make much-needed headway against T-cell ALL, and perhaps other tumors as well.

A study team led by Alejandro Gutierrez, MD, and A. Thomas Look, MD, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and Jon Aster, MD, PhD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, reported the results Jan. 9 in the Journal of Clinical Investigation.

T-ALL is rarer and more aggressive than the B-cell form of ALL, and it has a relatively poor prognosis. Despite improvements in the treatments available, 20 percent of children and more than 50 percent of adults diagnosed with T-ALL succumb to it.


To identify possible new treatment options, Gutierrez, Look and their collaborators screened a library of 4,880 compounds — including FDA-approved drugs whose patents had expired, small molecules and natural products — in a model of T-ALL engineered using zebrafish.

Strategies that identify new uses for existing drugs have grown in popularity in recent years as a way of quickly developing new disease therapies. Zebrafish models are cost-effective platforms for rapidly conducting drug screens, as well as basic stem cell, genetic, cancer and developmental research.

“We wanted to see if there were drugs or known bioactive molecules that are active against T-ALL that hadn’t been tested yet,” Look explained. “There may be drugs available for other indications that could be readily repurposed if we can show activity.”

One of the strongest hits in the zebrafish screen was the drug perphenazine. It is a member of the phenothiazines, a family of antipsychotic medications used for 50 years, because they can block dopamine receptors.

The team verified perphenazine’s anti-leukemic potential in vitro in several mouse and human T-ALL cell lines. Biochemical studies indicated that perphenazine’s anti-tumor activity is independent of its psychotropic activity, and that it attacks T-ALL cells by turning on PP2A.

The fact that perphenazine works by reactivating a protein shut down in cancer cells is itself novel in the drug development field.

“We rarely find potential drug molecules that activate an enzyme,” Gutierrez explained. “Most new drugs deactivate some protein or signal that the cancer cell requires to survive. But, here, perphenazine is restoring the activity of PP2A in the T-ALL cell.”

Gutierrez and Look, along with their collaborators, are now working to better understand the interactions between PP2A and perphenazine. They also want to search for or develop molecules that bind to and activate the enzyme more tightly and specifically to avoid perphenazine’s psychiatric effects.

“The challenge is to use medicinal chemistry to develop new PP2A activators similar to perphenazine and the other phenothiazines, but to dial down dopamine interactions and accentuate those with PP2A,” Look said.

The researchers see future PP2A activators not as magic bullets but as potentially important additions to the oncologist’s arsenal when treating patients with T-ALL.

“T-ALL patients are often on the borderline between a long remission and a cure,” Look said. “If we can push the leukemia cells a little harder, we may get more patients who are actually cured. In this way, PP2A activators may, in combination with other drugs, make a real difference for patients.”

It may be that the benefits of PP2A-activating drugs could extend beyond T-ALL. “The proteins that PP2A suppresses, such as Myc and Akt, are involved in many tumors,” Look noted. “We are optimistic that PP2A activators will have quite broad activity against different kinds of cancer, and we’re anxious to study the pathway in other malignancies as well.”

This study was supported by the National Cancer Institute (grant numbers K08CA133103 and P01CA109901), the Leukemia and Lymphoma Society, the William Lawrence Blanche Hughes Foundation, the Bear Necessities Foundation, the Ligue Nationale contre le Cancer, Association Laurette Fugain, Institut National du Cancer (INCA), Universités Paris Diderot and Paris Sud, INSERM, CEA and Canceropole Ile de France, European Union’s Seventh Framework Programme and the American Society of Hematology. [en línea] Boston, MA (USA):, 23 de enero de 2014 [REF. 09 in January of 2014] Available on Internet:

Robotic radiotherapy

20 01 2014

The Provincial Hospital of Castello working on a project to discover which processes of intraoperative radiotherapy are susceptible to be automated using portable accelerators, so is determined to a cancer patient specific treatment a la carte for it.


El Equipo de Investigación del Hospital Provincial de Castelló

The research team of the Provincial Hospital of Castello

The research of the Atrium project team, promoted by the CV of the Provincial Hospital of Castello Foundation, the past met 26 December to advance the work of this research project which is expected to be completed within one year.


Juan López Tarjuelo, radiation physicist of the main hospital and research center of this project said yesterday that "the biggest advance of this study lies in analyzing processes of intraoperative radiation therapy are likely to be automated using portable accelerators, so a cancer patient is determined a specific treatment to the letter for him and this robotic system it can tune application to minimize the possible side effects of radiation therapy". of time, as noted by López Tarjuelo, the first step in this research will be to develop an absolute development of this technique in a theoretical setting and programming of a software to be able to start it for, in a second phase, to proceed to the robotization of the portable Accelerator.


In addition, the Castellón-based researcher stressed that "this investigation is allowing also make a study of patient safety during the intraoperative radiotherapy, so as to ensure full application to the patient's specific dosimetry which has been diagnosed you».


The director of the Fundación CV of the Provincial Hospital, Carlos Ferrer, He pointed out the importance of this study for the hospital Consortium, «Since our Center is one of the pioneers in this technique of application of radiotherapy while opera cancer patient». «We are one of the centres of reference in all Spain in the application of the intraoperative radiotherapy, but in addition, We still have aspirations to improve this technique as much as possible for the good of the patients, why our research teams are developing programs that are aimed both at improving the application of treatments as to the preservation of the security of the patient», added the doctor.


In the workshop were representing to the partners the project's principal investigators from the Gregorio Maranon Hospital in Madrid, the doctor Felipe Calvo, Head of the Department of radiation oncology of the Madrid Center and Illana Carlos, principal investigator of the company GMV, together with the representatives of the Polytechnic University of Catalonia.
 [en línea] Valencia (ESP):, 20 in January of 2014 [REF. 27 in December of 2013] Available on Internet: castello/2013/12/27/radioterapia-robotizada/1063559.html

Medical technology and economy

16 01 2014

Medical technology is the economical use of an invention become appliances, instruments, devices and mechanisms to diagnose, alleviate pain, reduce the risk of a disease or a condition and improvement of the quality of life of the patients, through the application of technological development. By misadventure, greater use of medical technology, communication with the patient is reduced to almost zero. It is difficult to imagine a hospital or a doctor's office without instruments with medical technology.

The factor most important and decisive for the development of medical technology is the integration of the economy, Science, Engineering and medicine. Devices such as x-ray X and magnetic resonance (MRI) they are based on advanced principles of physics, specifically designed by engineers, as dental parts “bridges and implants”.


The best way to describe medical technology is related to the use of devices and medical instruments, According to the definition of the European Commission in its US Medical Devices Directive. The definition of the term medical device is: any instrument, appliance, device software or material, used singly or in combination and manufactured to be used for diagnostic or therapeutic purposes in humans.


In all this there is a purpose of market, Economic and business, mainly in the design of the administrativa-organizacional structure, the education and training of staff, adequate facilities, modern laboratories for research and development, the generation of new materials, the improvement of the design of industrial processes, including microelectronics, telecommunications, Instrumentation, biotechnology, software development, Nano technology, micro electro mechanical systems, etc.


How important is the economic system around the medical technology? They exist the world over 500 thousand technologies in 20 thousand generic groups. These fall in 16 categories of products, as determined by the Global Medical Devices Nomenclature Agency.


United States leads world production of medical technology and at the same time is the main consumer. (However, its health care system is not the first in the world).


In this country it takes 130 billions of dollars annually for research of new medical technologies. One-third of that investment is provided by the Government. A trillion dollars over the past decade was reversed only in the research of new drugs.


Mexico does not develop medical technology: the purchase and consume it. This disadvantage is responsible for the rising cost of health care. In the United States is the 10 per cent of the annual increment. In Mexico becomes of the 30 to the 40 per cent. It is estimated that in general, medical technology is responsible for at least half of the medical costs increased. In addition, in Mexico, it is not within the reach of the majority of Mexicans.


United States possesses the largest market in the world for health care services, representing a significant portion of its economy. In 2010 the medical services industry came to 1.75 trillion in revenue, using more of 14 millions of people, equivalent to the 9 per cent of its workforce. The US Bureau of Labor Statistics estimates that the growth of the industry of medical technology will come to 3.2 million new jobs between 2013 and 2018.


Work related to the home health care and diagnostic laboratories are expected to grow more than the 40 per cent over the next 10 years. (However, is average in 98 MIL annual deaths in US hospitals for infections, negligence and medical errors, among them, the intensive and wrong use of disruptive technology. Example: excesses in the deadly levels of radiation in patients).


Such market value exceeded the 10 billones en 2012, representing the 38 per cent of the total of the medical technology industry. The export of medical technology controlled by the Department of Commerce was of 44.2 billones en 20billion incent increase in relation to 2011. The secret? Ongoing research, innovative technologies and highly competent and trained engineers.


In the care of health and patient care in 2010 United States hospitals had an income of 809 billions of dollars. United States account with 5 thousand hospitals. During the last 10 years annual revenues have increased consistently around the 5 per cent.

Twitter: @SalvadorGLignan

Corporate issues, Economic and political [en línea] Mexico D.F. (MEX):, 16 de enero de 2014 [REF. 02 in January of 2014] Available on Internet: secciones/finanzas/48552-tecnologia-medica-y-economia.html

Understand the therapeutic vaccination

13 01 2014

What is therapeutic vaccination and how it is being used to develop new strategies against HIV?


At the end of the 18th century, the British physician Edward Jenner took a little bit of pus from a pustule caused by smallpox from cattle and inoculated it into the arm of an eight-year-old boy to see if exposure to the virus that contained (Vaccinia variola) It served to protect the child against its deadliest and distant relative, smallpox virus. It is possible that the experiment was very unethical according to current standards, but his success revolutionized the preventative medicine and converted to Jenner, in the eyes of many people, in the founding father of Immunology.

Also, gave us the word "vaccine", that is currently used to describe substances of different nature that are given to prevent disease, as the live attenuated virus or disabled during the flu vaccine injections, or molecular fragments of HIV employees for the AIDS vaccine candidates. Although approved and experimental vaccines that fail to prevent infections could also reduce the severity of the disease-causing, in general tends to relate vaccination with prevention of one infection rather than with your treatment (see 'Core issues' of the VAX may of 2009, 'Understanding how evaluate the partially effective vaccine candidates').


But, in recent times, a completely different type of vaccine has become the focus of intense scientific research: therapeutic vaccines. These are being designed today to take advantage of the immune response so that you can treat ailments ranging from cancer to multiple sclerosis. In the field of HIV also attempted develop therapeutic vaccines hoping to delay or prevent the onset of AIDS in people with the virus. The first person to try this approach was the French scientist Daniel Zagury, What, in 1986, It inoculated with two women with HIV of Zaire (today, the Democratic Republic of the Congo) a version modified genetically in a protein of HIV. To transport fragments of the virus, Zagury employed a viral vector of the virus Vaccinia used in the smallpox vaccine. Shortly after, the researcher tested the candidate in eight others with HIV.


However, the research of Zagury sparked controversy, Since the vaccine had not been tested adequately in preclinical studies and, for this reason, It did not have the approval of the French regulatory body for testing. To make things worse, three of the vaccinated people died due to a severe progressive necrosis that developed in the injection point, a reaction to the virus Vaccinia recombinant used as vector (There has also been this rare complication in people with weak immune systems, vaccinated against smallpox). This delayed the search for a therapeutic vaccine and this field languished for years.


The dawn of the TARGA


It was necessary to the introduction of highly active antiretroviral therapy (TARGA) in 1996 to revive this field and, currently, Some scientists consider that therapeutic vaccination can be a valuable component of experimental therapies to cure HIV infection. The three (or more) used combined on the HAART drugs can suppress viral replication in blood, allowing the body to rebuild his immune system. But these regimes, by themselves, they cannot cure HIV infection, Since the virus is hidden in the t-cell chromosome sleepers, creating a population of cells with latent infection, known as a viral reservoir. As the virus is not replicated in these t-cells, is not affected by the TARGA.


Although it is not clear how they are formed or are kept this latent reservoirs, they have become the central focus of the research in the cure of HIV. It is believed that a way to cure this infection could be locate and eliminate reservoirs. For example, in a clinical trial recently with people living with HIV who took HAART and had an undetectable viral load, We used a drug used in chemotherapy called vorinostat to activate HIV in dormant cells in the hope of eliminating these reservoirs and clear up the infection by the virus. However, other more recent studies revealed that nor the application of simple or multiple doses of this drug allowed to clarify the infected cells, which indicates it will probably need to use mixed strategies to achieve this goal.


The scientific and pharmaceutical companies, also, they have been testing other drugs to locate latent HIV and eradicate it, or leave it exposed to the immune attack. The hope is that even if these approaches leave patients with residual HIV infection, they have reduced enough presence of virus to achieve what is known as a functional cure.


Where you enter therapeutic vaccination in all this? It is believed that the activation of an immune cell called CD8 T lymphocyte, that destroys other cells infected by virus, It would help to remove the exposed cells of the viral reservoir. Unfortunately, previous studies have shown that responses of t CD8-cells induced in persons with HIV were not large or powerful enough to control the virus. Today, you are attempting to remedy this problem by enhancing CD8 responses by therapeutic vaccines.


The hope is to first administer compounds to expose latent virus and then perform a therapeutic vaccination could allow the Suppression of HIV indefinitely without having to rely on the daily administration of antiretroviral. Also candidates for therapeutic vaccines are being evaluated as one-size-fits-all strategy to combat HIV once stops HAART. One candidate tested in a phase I trial of recent form contained a subset of dendritic cells. These specialized immune cells act as first responders, detecting viruses and inducing immune responses to act on them. Unfortunately, This experimental vaccine tested on a small group of people in Spain did not work it sufficiently well as to keep people with HIV without TARGA too long (see 'International news' of the VAX in January of 2013).


On the other hand, It has been shown in animal studies to therapeutic vaccination could reduce further and actively suppress levels of residual virus after the TARGA. Even though the animals were taking antiretrovirals, further reduced the average monkey viral load some 100 copies/mL of blood. When antiretroviral therapy is interrupted, eight weeks after the last vaccination, the average viremia not bounced in vaccinated animals.


Although there is still much ahead, the research team hopes that therapeutic vaccines can offer an alternative strategy to the daily routine of shots involving HAART to people living with HIV.


Regina McEnery [en línea] Barcelona (ESP):, 13 in January of 2014 [REF. 09 April of 2013] Available on Internet:

ECRI 2014: Risks of medical technology forecast.

9 01 2014

The clinical engineers warn that the training would reduce the danger


The ECRI Institute of the United States has just published the report 'Top 10 Health Technology Hazards for 2014’, that collects the main healthcare technologies on which the professionals of the sector should pay careful attention next year because of the risks associated with its use. Like this, as on previous occasions, the professionals of the Spanish society of Electromedicine and clinical engineering (IEEE), as experts directly involved in the use of this technology, They carried out an assessment of this list.


The ECRI Institute stands out as potential sources for 2014 some risks arising from the incorrect use of medical apparatus. Like this, at the top of the ranking are the risks associated with medical device alarms, followed by the error on the use of infusion pumps of drugs or the inadequacy of endoscopes and material processing surgical risks. In addition, This institution also highlights the labour and pediatric risks associated with ionizing radiation.


"The ECRI Institute collects in this list risks associated with some of the medical devices in the proliferation of face to the next year, linked mainly to misuse them or human errors. For this reason, It is necessary that health professionals aware of the correct use of the technology for the sake of safe health care and quality, and take the appropriate measures, that you go through the professional qualification, the provision of adequate means, the realization of checks as well as security controls", explained Pedro Jesus Manzanares Pedroche, President of the IEEE.


Alarms of medical devices are placed at the top of the list of ECRI, as one of the main elements to be considered by health professionals, that can come from physiological monitors, fans, infusion or other medical devices pumps. In this sense, ECRI notes that there is an excessive number of alarms (the most clinically insignificant) that you are causing a supersaturation of notices between caregivers or health professionals who receive them.


This oversaturation can result in loss of important alarms and expose, Like this, to unnecessary risks to patients in cases that the alarm is not activated when it should or that the signal does not communicate properly the health team or do not include sufficient information about the same. "As it shows the ECRI Institute, programs whose goals are to minimize the number of clinically insignificant alarms must be switched, optimize the notification of these notices and respond with established protocols", has asserted the President of the Seeic.

As for errors in drug infusion pumps, ECRI recommended to minimize the risk of errors in the use of these devices with a continuing workforce education, to ensure that users of these devices receive proper instructions. In addition, This institution recommends that when you buy new infusion pumps the usability problems are taken into account and always involves personnel responsible and qualified hospital in the process of evaluation of these devices. in that sense, Jesus Manzanares recalls that it is essential is to expedite the implementation of medical services in our country to ensure both this type of technology as its correct maintenance assessments, with the creation of the figure of the head of medical service in, at least, hospitals with more of 250 beds, in support of the professional qualifications in Electromedicine (Royal Decree 328/2008).


Pediatric and labour risks associated with ionizing radiation

Jesús Lucinio Manzanares, presidente de la Seeic.

Pedro Jesus Manzanares, President of the Seeic.

Also pay special attention to the risks associated with the use of health technology emitting ionizing radiation (X ray), According to the report. They must be implemented, as it is advisable to ECRI, health centers and hospitals that have this type of technology, protection programs that will ensure the necessary knowledge for the medical team, as well as the technology to minimize exposure to this type of radiation in Spain., an important step, According to highlights of the IEEE President, It has been accredited a few months ago by the Ministry of industry of the Canary Islands, backed by the Consejo de Seguridad Nuclear, for the registration of the service of biomedical engineering of the University Hospital complex of Canary Islands (HUC) as a company authorized to the technical assistance of X-ray equipment for the purpose of medical diagnosis. "It is the first time that a hospital is authorized in Spain for this activity with our own staff, formed and trained in electro-medicine", recalled Manzanares. in addition, ECRI warns about exposures from pediatric patients to this type of radiation emitted by CT (TC). This imaging technology is a valuable diagnostic tool but it is not without risk, especially for patients who are more sensitive to the effects of ionizing radiation than adults. Some recently published studies demonstrate that exposure to this type of radiation in the infantile stage increases the risk of developing diseases such as cancer in adulthood, the report of ECRI. "is necessary that be followed of control appropriate procedures in the use of diagnostic technology by image in the pediatric population because", as noted by ECRI, may result in errors that can affect the safety of the patient arising from the application, for example, the protocols of the adult patient in the pediatric patient, so it is necessary to the use and maintenance of this technology by qualified professionals", explained the President of the Seeic.


The same study in Spain

The objectives pursued by the ECRI Institute with the publication of this article, which is updated on a regular basis, They range from providing independent and objective when it comes to trial, manage and use devices, equipment and medical systems, be a center of information on hazards and deficiencies of the sanitary products, to promote medical devices through a market better informed. "in Spain there a body that plays a role similar to the ECRI Institute, impartial, aseptic and realistic, that measure, evaluate, and ultimately, change the current model of evaluation of health technology. This body should carry out, among other measures, an analysis of cost/effectiveness of the process as a whole and a paradigm shift towards an agency responsible for such analysis", said Manzanares. [en línea] Madrid (ESP):, 09 in January of 2014 [REF. 04 in December of 2013] Available on Internet: http://secciones/tecnologia/la-alarma-de-los-dispositivos-medicos-principal-riesgo-en-el-ranking-del-ecri-3107

Bio-Retina: the Bionic eye that will return sight to the blind

6 01 2014

Nano-Retina It is the name of the company that has managed the scientific miracle. In the israeli city of Herzliya, its scientists have developed a micro-device, After being implanted in the back of the eye, mimics the functioning of the retina, catching visual signals with a tiny camera and then transforming them into electrical signals that stimulate the neurons responsible for creating images in the brain.


No bigger than a grain of rice, the "Bio-Retina" is a device that promises to revolutionize the world of science and health. Although it is still in process of development, its creators claim to have tested successfully in pigs, and that in two years will be available for humans.

According to statements made to the news agency EFE, by Raanan Gefen, Executive Director of Nano-Retina, "in a week the patient can immediately see. We wanted to provide a blind person of suitable vision that allows them to function in society and be totally free, walk through family sites and see their loved ones".

According to the company, the "Bio-Retina" is implanted through a simple operation of 30 minutes under local anesthesia, very similar to correction of cataract interventions. A week later, the patient may enjoy a view of 600 pixels, the most advanced technology can offer so far.

By now, the vision will also need to be only black and white, Although the company already reported efforts to integrate a gray scale that allows a user to differentiate tones and perceive shadows.

Patients undergoing this treatment, they will also have some limitations, as the fact of not being able to drive or read books with letters of standard size. Anyway, the situation of seeing absolutely nothing, the "Bio-Retina" saving presents a solution really.


YouTube Preview Image


The device would cost about 60 mil dólares, However, the company expects that insurers allowed to cushion the final price, so predicting a final price for the patient (including the intervention) of 2 mil dólares.thousand dollars

At the moment, the revolutionary invention will solve life to patients with retinitis pigmentosa and age-related macular degeneration (AMD, for its acronym in English), common disorders from the 60 years. Also, on the website of the company, They claim that the Bio-Retina would work to restore vision in diseases such as diabetic retinopathy, or those where the foto-receptor atrophies and can not work again because there is no cells that can translate the light falling on the retina in a useful vision.

Finally,the "Bio-Retina" can charge through sunglasses designed to transmit power wirelessly using a laser, It will not interfere at all with the function of the device, and they can be recharged at night.




Tecnews.PE [en línea] Lima (PER): tecnews.PE, 06 in January of 2014 [REF. 30 in December of 2013] Available on Internet: http://noticias/bio-retina-el-dispositivo-que-devolvera-la-vista-los-ciegos/

Where is the diagnostic market

2 01 2014

As medical technology advances, There is a very clear tendency of union between two formerly separate health business portfolio: drugs and diagnostic tests. The most classic example is in breast cancer: currently, When a woman receives the diagnosis, is already virtually forced the doctor to send you to apply certain tests known as markers, to define what kind of tumor attacked it, because according to this, It is possible to send the most appropriate medication that patient.


This means that diagnostic tests currently existing not only we know whether or not someone has the disease - in this case the cancer-, but it is feasible to define between a number of different types of cancerous tumors. Thus today it is also known that cancer is not a single disease, but it is a set of numerous types and subtypes of disease. Something similar is already happening with hepatitis C and cervical cancer, having Human Papilloma Virus test.

And as things are going, Depending on what you suffer, There will be a separate treatment for everyone. Therefore it speaks that we are heading to a medicine personalized for each patient.

One of the most advanced in this is the Swiss laboratories Roche, whose area of Roche Diagnostics is the world leader in this field and has been able to successfully bind its Pharma unit, that is to say, of drugs.

In fact, today its diagnostic business unit recorded sales for a few 10,000 million Swiss francs, and there is no great difference regarding what sells Roche drug that had been its traditional business as a pharmacist.

Uwe Oberlaender, the general director of diagnostics Roche in Mexico, mentions that it sold in diagnosis, They reinvest almost 10% in research and development, Since it is a business of high and constant innovation. He says that thanks to Diagnostics, Roche Farma may have more specialized medications because the studies it is possible to know is given to patients given drug. There is the case of Herceptin, a drug that is not chemotherapy (they are antibodies) and only applies to who have a very specific subtype of breast cancer (Her2 positive), with a virtually certain result of recovery.

With molecular testing, for example, expected that it may soon know if the daughter of a woman who died from breast cancer can develop equally evil. In fact, Roche has a huge apparatus in the Institute of cancerology, where being implemented a study with these tests in order to see what preventive measures can be taken between women who are more susceptible to this cancer.

According to Oberlaender, Roche now has about five approved drugs that already have their own marker or molecular testing, even recently in the United States the FDA has already approved a drug linked to a specific marker molecule, both Roche; It was the first time that it happens, but it is expected that many more come.

The tobacco companies are continuing to press...

It seems that the tobacco companies have not stopped pressing the Government and the legislature to work against illegal cigarettes. But the Cofepris, Mikel Arriola, He has not wavered in acting against that scourge, Although it has many other things to do; You can not engage only in that. Yesterday, Health Agency issued a report of actions against illegal tobacco requested the camera high last week.

Do you know some illegal cigarettes 100 apocryphal brands has seized the Cofepris in the 2013? More than 56 millions in eight States of the Republic; DF, Quintana Roo, Jalisco, Chihuahua, Chiapas, Durango, Coahuila and Oaxaca.


Maribel R. Colonel [en línea] Mexico, DF (MEX):, 02 in January of 2014 [REF. 10 in December of 2013] Available on Internet: